Furthermore, combining CAF-targeted HA degradation with PD-1/PD-L1 blockade significantly increased tumor-infiltrating T cells in a syngeneic breast cancer model, thereby amplifying the antitumor responses to immune checkpoint therapy. The gene discussed is PDCD1; the disease is breast cancer.